全文获取类型
收费全文 | 192070篇 |
免费 | 3899篇 |
国内免费 | 424篇 |
专业分类
耳鼻咽喉 | 2741篇 |
儿科学 | 7376篇 |
妇产科学 | 5824篇 |
基础医学 | 24819篇 |
口腔科学 | 5716篇 |
临床医学 | 14945篇 |
内科学 | 34434篇 |
皮肤病学 | 4469篇 |
神经病学 | 11388篇 |
特种医学 | 10552篇 |
外国民族医学 | 97篇 |
外科学 | 28825篇 |
综合类 | 1077篇 |
一般理论 | 1篇 |
预防医学 | 16129篇 |
眼科学 | 4257篇 |
药学 | 13335篇 |
2篇 | |
中国医学 | 134篇 |
肿瘤学 | 10272篇 |
出版年
2018年 | 3452篇 |
2017年 | 3829篇 |
2016年 | 3112篇 |
2015年 | 4784篇 |
2014年 | 4188篇 |
2013年 | 3257篇 |
2012年 | 9629篇 |
2011年 | 4500篇 |
2010年 | 2070篇 |
2009年 | 3748篇 |
2008年 | 1877篇 |
2007年 | 2596篇 |
2006年 | 2863篇 |
2005年 | 10997篇 |
2004年 | 12492篇 |
2003年 | 8086篇 |
2002年 | 3318篇 |
2001年 | 4299篇 |
2000年 | 1660篇 |
1999年 | 5805篇 |
1998年 | 498篇 |
1995年 | 368篇 |
1992年 | 6852篇 |
1991年 | 7088篇 |
1990年 | 7335篇 |
1989年 | 6935篇 |
1988年 | 6461篇 |
1987年 | 6227篇 |
1986年 | 5946篇 |
1985年 | 5235篇 |
1984年 | 3585篇 |
1983年 | 2908篇 |
1982年 | 999篇 |
1981年 | 765篇 |
1980年 | 835篇 |
1979年 | 3827篇 |
1978年 | 2361篇 |
1977年 | 1781篇 |
1976年 | 1559篇 |
1975年 | 2473篇 |
1974年 | 3105篇 |
1973年 | 2738篇 |
1972年 | 2756篇 |
1971年 | 2741篇 |
1970年 | 2555篇 |
1969年 | 2464篇 |
1968年 | 2237篇 |
1967年 | 2163篇 |
1966年 | 1898篇 |
1965年 | 1131篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
2.
3.
<正>what is the rationale for immunotherapies in Parkinsonian syndromes(PS)? PS are neurodegenerative diseases which are clinically characterized by a hypokinetic phenotype in combination with additional motor and non-motor symptoms. One major patholog- 相似文献
4.
5.
Rodrigo Scaliante Moura Gerson Oliveira Penna Ludimila Paula Vaz Cardoso Maria Araci de Andrade Pontes Rossilene Cruz Heitor de Sá Gon?alves Maria Lúcia Fernandes Penna Mariane Martins de Araújo Stefani Samira Bührer-Sékula 《The American journal of tropical medicine and hygiene》2015,92(6):1280-1284
The uniform multidrug therapy clinical trial, Brazil (U-MDT/CT-BR), database was used to describe and report the performance of available tools to classify 830 leprosy patients as paucibacillary (PB) and multibacillary (MB) at baseline. In a modified Ridley and Jopling (R&J) classification, considering clinical features, histopathological results of skin biopsies and the slit-skin smear bacterial load results were used as the gold standard method for classification. Anti-phenolic glycolipid-I (PGL-I) serology by ML Flow test, the slit skin smear bacterial load, and the number of skin lesions were evaluated. Considering the R&J classification system as gold standard, ML Flow tests correctly allocated 70% patients in the PB group and 87% in the MB group. The classification based on counting the number of skin lesions correctly allocated 46% PB patients and 99% MB leprosy cases. Slit skin smears properly classified 91% and 97% of PB and MB patients, respectively. Based on U-MDT/CT-BR results, classification of leprosy patients for treatment purposes is unnecessary because it does not impact clinical and laboratories outcomes. In this context, the identification of new biomarkers to detect patients at a higher risk to develop leprosy reactions or relapse remains an important research challenge. 相似文献
6.
7.
Entomopathogenic nematodes (EPNs) in the genera Heterorhabditis and Steinernema are lethal parasites of insects that are of interest as models for understanding parasite-host interactions and as biocontrol agents for insect pests. EPNs harbor a bacterial endosymbiont in their gut that assists in insect killing. EPNs are capable of infecting and killing a wide range of insects, yet how the nematodes and their bacterial endosymbionts interact with the insect immune system is poorly understood. Here, we develop a versatile model system for understanding the insect immune response to parasitic nematode infection that consists of seven species of EPNs as model parasites and five species of Drosophila fruit flies as model hosts. We show that the EPN Steinernema carpocapsae, which is widely used for insect control, is capable of infecting and killing D. melanogaster larvae. S. carpocapsae is associated with the bacterium Xenorhabdus nematophila, and we show that X. nematophila induces expression of a subset of antimicrobial peptide genes and suppresses the melanization response to the nematode. We further show that EPNs vary in their virulence toward D. melanogaster and that Drosophila species vary in their susceptibilities to EPN infection. Differences in virulence among different EPN-host combinations result from differences in both rates of infection and rates of postinfection survival. Our results establish a powerful model system for understanding mechanisms of host-parasite interactions and the insect immune response to parasitic nematode infection. 相似文献
8.
Eva Barragán María Carmen Chillón Remedios Castelló-Cros Nerea Marcotegui María Isabel Prieto Montserrat Hoyos Raffaella Pippa Marta Llop Amaia Etxabe José Cervera Gabriela Rodríguez Ismael Bu?o José Rifón Jorge Sierra Marcos González María J. Calasanz Miguel A. Sanz María D. Odero 《Haematologica》2015,100(5):e183-e185
9.
About 10% of patients with Lyme disease continue to experience musculoskeletal pain and cognitive dysfunction after recommended antibiotic treatment. This condition is called post-Lyme disease syndrome (PLDS) or post-treatment Lyme disease syndrome. These two terms are used interchangeably. The pathogenesis of PLDS has been controversial. The hypothesis that patients with PLDS may harbor hidden reservoirs of Borrelia burgdorferi after their initial antibiotic treatment is difficult to accept. The prospective, double-blind studies contradict this point of view. Also, recently published research applying xenodiagnosis to PLDS supports the opinion that PLDS most likely has an autoimmune background. Lengthy courses of antibiotics are not justified in patients with PLDS because of the lack of benefit, and they are fraught with hazards. Most patients with PLDS recover from persistent symptoms with time. However, it can take months before they feel completely well. 相似文献
10.
It is estimated that in Poland about 400,000 persons in general suffer from inflammatory joint diseases, including rheumatoid arthritis (RA). Epidemiological surveys documenting the frequency and disturbance of musculoskeletal disorders in the Polish population are few in number. Most of the estimations are based on epidemiological data from other countries (prevalence of 0.5–1%). According to the data of the National Health Fund in Poland 135,000–157,000 persons in total are treated because of rheumatoid arthritis per year [ICD10 (International Statistical Classification of Diseases and Related Health Problems): M05, M06]. In the case of this group of diseases indirect costs significantly outweigh the direct costs. Indirect costs increase together with activity level of the disease. The cost analysis of productivity loss of RA patients indicates that sickness absenteeism and informal care are the most burdensome. At the national level it amounts in total from 1.2 billion to 2.8 billion PLN per year, depending on the method of analysis. These costs could be significantly reduced through early diagnosis and introduction of effective treatment. 相似文献